CTI BioPharma Announces Outcome From End-of-Phase-2a Meeting With U.S. Food and Drug Administration (FDA) Regarding Pacritinib for Treatment of Myelofibrosis; - Company Plans to Advance Pacritinib 200 mg Twice-Daily (BID) Dose to Phase 3 for Patients With

Press/Media

Period18 Jul 2019

Media coverage

2

Media coverage

  • TitleCTI BioPharma Announces Outcome From End-of-Phase-2a Meeting With U.S. Food and Drug Administration (FDA) Regarding Pacritinib for Treatment of Myelofibrosis; - Company Plans to Advance Pacritinib 200 mg Twice-Daily (BID) Dose to Phase 3 for Patients With
    Media name/outletPR Newswire
    Country/TerritoryUnited States
    Date18/07/19
    PersonsJohn Mascarenhas
  • TitleCTI BioPharma Announces Outcome From End-of-Phase-2a Meeting With U.S. Food and Drug Administration (FDA) Regarding Pacritinib for Treatment of Myelofibrosis; - Company Plans to Advance Pacritinib 200 mg Twice-Daily (BID) Dose to Phase 3 for Patients With
    Media name/outletPR Newswire
    Country/TerritoryUnited States
    Date18/07/19
    PersonsJohn Mascarenhas